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A B S T R A C T
In this paper we explore the phenomenon of pleiotropy in neurodegenerative diseases, focusing on Alzheimer's
disease (AD). We summarize the various techniques developed to investigate pleiotropy among traits, elabor-
ating in the polygenic risk scores (PRS) analysis. PRS was designed to assess a cumulative effect of a large
number of SNPs for association with a disease and, later for disease risk prediction. Since genetic predictions rely
on heritability, we discuss SNP-based heritability from genome-wide association studies and its contribution to
the prediction accuracy of PRS. We review work examining pleiotropy in neurodegenerative diseases and related
phenotypes and biomarkers. We conclude that the exploitation of pleiotropy may aid in the identification of
novel genes and provide further insights in the disease mechanisms, and along with PRS analysis, may be ad-
vantageous for precision medicine.
1. Introduction
Neurodegenerative diseases are a group of disorders that are char-
acterised by the progressive loss of the structure and function of the
central nervous system. Examples of neurodegenerative disorders in-
clude Alzheimer's disease (AD), Dementia with Lewy bodies (DLB),
Frontotemporal lobar degeneration (FTLD) with frontotemporal de-
mentia (FTD) being one of its subgroups, Parkinson's disease (PD), and
Amyotrophic lateral sclerosis (ALS). These diseases are heterogeneous
in their pathophysiology; although they often present overlapping
phenotypes (Gitler et al., 2017).
Fifty million people have dementia world-wide, with 10 million new
diagnoses each year (Collaborators, 2019). AD is the most common
form (60–70%) of dementia. The fully penetrant mutations in APP,
PSEN1 and PSEN2 genes explain only 1% of AD (Hardy and Selkoe,
2002), whereas common forms of AD have heritability estimates of
0.58–0.79 (Gatz et al., 2006). The field of AD genetic research has now
produced extensive evidence that other genes may contribute to disease
development in AD. The APOE gene on chromosome 19 remains the
strongest genetic risk factor associated with the common late-onset
form of AD (Kunkle et al., 2019; Saunders et al., 1993). Genome-wide
association studies (GWAS) have shown to be the most successful ap-
proach in identifying the genetic underpinnings of common forms of
AD. Since 2009, nearly 40 risk loci have been identified which have
been found to associate with AD at the genome-wide level of sig-
nificance (Jansen et al., 2019; Kunkle et al., 2019; Lambert et al., 2013;
Marioni et al., 2018). Although APOE is the strongest predictor of late
onset AD, the genetic SNP-based heritability explained by this locus is
not high (0.05) (Escott-Price et al., 2017b) compared to genome-wide
estimates (0.24–0.53) (Lee et al., 2013a; Ridge et al., 2016; Ridge et al.,
2013). DLB is the second most common form of dementia, accounting
for 1 in 7 post-mortem diagnoses (Vann Jones and O'Brien, 2014). DLB
shows strong evidence that genes play a significant role in disease de-
velopment (SNP-based heritability estimates: 0.31–0.6 (Guerreiro et al.,
2016; Guerreiro et al., 2019). FTD is the second most common form of
young-onset dementia after Alzheimer's Disease (AD) (Ratnavalli et al.,
2002). FTLD can also co-occur with motor neuron disease (FTD-MND,
or FTD-ALS) in a continuous spectrum of phenotypes (Strong et al.,
2017). In a study by Rohrer et al., 10% of patients with FTLD had an
autosomal dominant history and heritability varied between the dif-
ferent clinical syndromes with behavioural variant frontotemporal de-
mentia being the most heritable (Rohrer et al., 2009). PD is a common
neurodegenerative movement disorder, affecting 1–2% of the popula-
tion over the age of 60. PD patients are affected by different combi-
nations of motor and non-motor symptoms, e.g. tremor, rigidity, fa-
tigue, loss of smell. In the most recent GWAS, it was shown that genetic
factors that are common in the population make a substantial con-
tribution to PD, with heritability estimates of 0.16–0.36 explained by
common variants (Goldman et al., 2019; Nalls et al., 2019). Finally, ALS
is a progressive neurodegenerative disorder of motor neurons caused by
the interplay of environmental and genetic factors acted on by time (Al-
Chalabi and Hardiman, 2013) with total heritability estimates 0.76
from twin studies (Al-Chalabi et al., 2010), and 0.40–0.60 in family
studies (Wingo et al., 2011), whereas the SNP-based heritability is
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estimated 0.21 (Keller et al., 2014).
Recent studies have shown that different complex human traits are
genetically correlated, including disorders of the brain (Anttila et al.,
2018). This correlation may in part be explained by a phenomenon,
formally known as “pleiotropy” (Sivakumaran et al., 2011). Pleiotropy
occurs when a genetic locus affects more than one trait and it is one
possible underlying cause for an observed cross-phenotype association
(Solovieff et al., 2013). Since neurodegenerative conditions are highly
comorbid, with certain pairs of neurodegenerative diseases being ge-
netically more similar than others, the joint analysis of related pheno-
types has the potential to uncover additional associations. The pleo-
tropic loci may also point to shared biological mechanisms, which may
help to filter out spurious associations by reducing the noise and thus
improving prediction accuracy. Importantly, highly pleiotropic SNPs
are more likely to be genic (exonic or intronic), and less likely to be
tissue specific (Watanabe et al., 2019). Moreover, pleiotropic loci have
the potential to serve as targets for interventions that simultaneously
prevent or treat multiple diseases. Various methods have been devel-
oped that exploit pleiotropic effects and several studies have been
conducted in an effort to identify novel genetic associations in neuro-
logical disorders.
Despite these GWASs being conducted and hundreds of genomic
regions being implicated in various neurodegeneration related traits,
these findings have not been translated into clinically useful risk pre-
diction models. For precision disease prevention and treatment, GWAS
associated Single Nucleotide Polymorphisms (SNPs) typically account
for only a small fraction of the total heritability and thus, cannot pro-
vide satisfactory prediction accuracy (Manolio et al., 2009). It is now
established that the genetic architecture of most neurodegenerative
disorders is highly polygenic (Escott-Price et al., 2015b; Ibanez et al.,
2019; Nalls et al., 2019)
The polygenic risk score (PRS) offers a calculation of genetic risk for
a disease or a trait based not solely on genome-wide significant SNPs,
but on all nominally associated variants (typically thousands of var-
iants). A PRS for a trait is defined as the weighted sum of risk variants,
where the weights associated with them are usually taken from a
powerful GWAS for that trait/disease. Therefore, the PRS accounts for
the small effects of a large number of SNPs which still contribute to
disease risk, successfully capturing the polygenicity of a disease. PRS
has been widely used for identifying and/or predicting an individual's
disease risk (Escott-Price et al., 2015a; Escott-Price et al., 2015b; Ibanez
et al., 2017) and for studying genetic overlap between disorders traits
(Chaudhury et al., 2019; Creese et al., 2019; McLaughlin et al., 2017).
In this review we sought to 1) to summarize the statistical techni-
ques that can be used to identify pleotropic genes and regions, 2) to
discuss the biological mechanisms that are common between neuro-
degenerative disorders, 3) to explain how heritability estimates are
related to the prediction accuracy by the PRS and 4) to explore how PRS
analysis can be utilised to model the genetic risk of pleiotropic regions
for prediction of shared sub-phenotypes in neurodegeneration.
2. Approaches to investigate pleiotropy
Various methods have been developed to assess the common un-
derpinnings among diseases in both genome-wide and regional level, as
well as in single-variant level. These multi-trait approaches vary con-
siderably in the statistical techniques they employ and the study design
considerations they are based on, including the type and number of
traits and the type of data needed (individual-level genotype or sum-
mary statistics data).
2.1. Genome-wide and regional approaches
Genetic correlation between traits on the genome-wide scale can be
used as an initial assessment of the global genetic overlap between two
traits. The latter can be inferred by applying the PRS method to two
trait GWAS datasets (Purcell et al., 2009). This method uses markers
selected from the summary GWAS data in one sample to construct a
weighted genetic risk score for each individual in an independent
sample. An association between this composite score and the trait of
interest in the second sample is evidence of an overlap between the
polygenic architecture of each trait.
In like manner, there are a number of multivariate methods for
genetic correlation analysis GCTA (Lee et al., 2013b), BOLT-REML (Loh
et al., 2015) and mvLMM (Furlotte and Eskin, 2015)) which use in-
dividual-level genotype data, limiting their usage due to restrictions
around data sharing.
More recently, the LD score regression approach (LDSC) (Bulik-
Sullivan et al., 2015) has gained popularity for the investigation of
genetic correlation between traits, as only summary statistics data are
required for this analysis. This approach is also easy to use and very
indicative of potential pleiotropy between traits, but it does not provide
information at an individual SNP level. Finally, a recently published
method, GNOVA (Lu et al., 2017), was developed to allow the strati-
fication of genetic covariance by functional genome annotation, en-
abling the investigation of the shared genetic basic between complex
phenotypes. It should be noted that genetic correlation is not the same
as pleiotropy; zero correlation does not indicate the absence of common
risk loci between two traits as there could be lack of directionality to
the genetic relationship (i.e. at some shared loci the risk allele is the
same for both traits, whereas at others the same allele can increase the
risk for one trait but be protective for the other). A technique addres-
sing the latter has been proposed named ρ-HESS (Shi et al., 2017), that
finds specific regions with strong correlation that could serve as puta-
tive causal models between traits.
2.2. Single-variant approaches
In the signal-variant level, the simplest approaches which are
commonly used to explore association of genetic variants with multiple
correlated phenotypes are 1) examination of single-trait summary sta-
tistics and reporting cross-phenotype associations for loci reaching the
significance threshold for each trait, and 2) testing loci known to be
associated with a given phenotype for association with another phe-
notype i.e. reporting loci reaching the significance threshold for the
second phenotype (Desikan et al., 2015). These approaches can be
underpowered, thus various methods that statistically combine sum-
mary data for multiple traits have been developed.
Meta-analysis methods combining GWAS summary statistics via
conventional inverse-variance meta-analysis increase power but also
pose methodological challenges when different studies are capturing
heterogeneous and/or pleiotropic phenotypes. In the case of pleiotropy,
individual variants are likely to be associated with only a subset of the
traits analysed, or they might even demonstrate effects in different di-
rections for the different phenotypes under analysis. Generalisations
and modifications of the meta-analyses for the discovery of pleotropic
single-variants include the Cross Phenotype Meta-Analysis (CPMA)
(Cotsapas et al., 2011), the Association analysis based on SubSETs
(ASSET) (Bhattacharjee et al., 2012), the Cross Phenotype ASSOCiation
(CPASSOC) (Zhu et al., 2015), the R package MultiMeta (Vuckovic
et al., 2015) and the Multi-Trait analysis of GWAS (MTAG) (Turley
et al., 2018). CPMA tests whether a SNP has multiple phenotypic as-
sociations across different traits that might have a common genetic
background, such as autoimmune diseases. It can detect variants that
are associated to at least a subset of, though not necessarily all, diseases
by examining the deviation in the distribution of associations; however,
this method cannot be applied to studies with sample overlap (Cotsapas
et al., 2011). On the contrary, ASSET, CPASSOC and MTAG are robust
to sharing the same controls, which is essential when summary statistics
data come from large consortia. The ASSET technique explores all
possible subsets of traits with non-null associations to identify the one
with the maximum Z-statistic and evaluate its significance while
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accounting for multiple testing. This method allows a subset of traits to
have no effect, or for the effect of the susceptibility loci to manifest in
different directions (Bhattacharjee et al., 2012). The MTAG approach is
based on the key assumption that all variants have the same effect sizes
across the traits and produces trait-specific association statistics. It can
be specifically useful for a trait that is underpowered but shows strong
genetic correlation with other traits. However, the application of MTAG
to a large number of low-powered studies could cause large inflations to
the False Discovery Rate (FDR) (Turley et al., 2018). CPASSOC was
developed to work for both univariate and multivariate summary sta-
tistics data and it allows for heterogeneity of effects for the same or
different phenotypes across studies (Zhu et al., 2015). Finally, the R
package MultiMeta is applied to a multivariate setting by allowing
different effect estimates (weights) for each marker (Vuckovic et al.,
2015).
Extending the empirical Bayesian false discovery rate (FDR) (Efron
and Tibshirani, 2002), the Bayesian conditional FDR (cFDR) approach
is based on the notion that if two diseases share a common genetic
background, a degree of association with one trait may increase the
likelihood of detecting an association with the second trait (Andreassen
et al., 2013). The Mendelian Randomization approach (Smith and
Ebrahim, 2004) uses information on the association of one or several
SNPs with each trait to infer whether or not trait A causally influences
trait B (known as “mediated pleiotropy”). It can be used to detect
mediated pleiotropy compared to the above-mentioned methods that
aim to detect biological pleiotropy (Solovieff et al., 2013). Finally,
BUHMBOX (Han et al., 2016) is aimed at detecting spurious pleiotropy
by examining whether alleles with shared risk are observed due to
sharing among all individuals or a subset of individuals, in a genetically
heterogeneous cohort.
3. Risk prediction in neurodegeneration with polygenic risk
scores
The genetic architecture of the majority of neurodegenerative dis-
eases includes many common variants of small effect that are likely to
reflect a large number of susceptibility genes and a complex set of
biological pathways related to disease. While the polygenic method
introduces noise by including some variants that are not involved in
disease susceptibility (i.e. false positives), this has been shown to be
offset by the increased power to identify those at highest/lowest risk of
disease (Consortium, 2014; Escott-Price et al., 2015b).
PRS analysis has recently shown that there is a significant polygenic
contribution to neurodegenerative diseases. A large polygenic con-
tribution to the overall heritable risk of AD has been reported by
(Escott-Price et al., 2015b). Since the whole genome captures a much
higher proportion of genetic variability (0.24–0.53) than APOE alone
(0.05–0.13) (Escott-Price et al., 2017b; Lee et al., 2013a; Ridge et al.,
2016), the prediction accuracy using PRS is higher, with an of
AUC = 75%–84% in clinical and pathology confirmed samples re-
spectively (Escott-Price et al., 2017a; Escott-Price et al., 2015b). When
APOE is included in the PRS, the majority of the people at the high
extreme of the PRS distribution possess ε4 allele(s), however the pre-
dictive accuracy of PRS in pathologically confirmed ε3 homozygotes is
also high and is equivalent to the predictive accuracy of the whole
dataset (Escott-Price et al., 2019).
In PD, a polygenic basis has been confirmed and shown to correlate
with age at disease onset (Escott-Price et al., 2015a). However, the PRS
analysis requires large discovery sample sizes to estimate the effect
sizes of risk alleles as accurately as possible. The GWAS sample sizes for
FTD, DLB, ALS are not as large as AD or PD, and therefore no PRS has
been attempted for these diseases (Ibanez et al., 2019). In addition,
diseases like FTD and ALS are very heterogeneous and can be stratified
into different subtypes, reducing the sample size for each group and
thus the power of the GWAS and the PRS analyses.
A common pitfall is to directly compare prediction accuracy by PRS
and known strongly associated regions/genes (e.g. APOE) with the
heritability estimates. Two main measures (R2 - the proportion of var-
iance explained and AUC - Area Under the receiver operator Curve) are
routinely used to report the quality of prediction by the PRS. R2 is di-
rectly linked to the heritability captured by SNPs and is usually quite
small.
To illustrate this, we use AD as an example. For AD the R2 is 0.16 for
APOE alone and 0.1 for the PRS excluding APOE locus (in house ana-
lysis in GERAD data (Baker et al., 2019) using summary statistics from
(Kunkle et al., 2019)). AUC is the accuracy of the prediction, comparing
the observed case/control status and the predicted classification esti-
mated by a logistic regression model. It provides an aggregate measure
of performance across all possible classification thresholds. An AUC of
50% indicates that the model cannot discriminate between cases and
controls. For AD, the AUC is 67% for APOE alone and 63% for PRS
without APOE (Escott-Price et al., 2015b). When the two variables
(APOE and PRS) are combined, the AUC for the joint prediction is 75%.
An explanation for this can be found in (Wray et al., 2019). The
expected value of R2 (E(R2)) is the SNP-based heritability (h2) divided
by the sum of one plus the ratio of the number of SNPs (M) by the
sample size (N) times h2)
=
+
E R h
M Nh
( )
1 /( )
.2
2
2
The SNP-based heritability is a value between 0 and 1. If M is small
and N is large, then the ratio M/(Nh2) tends to zero, and E(R2) ap-
proximately equals the heritability (h2). However, when the number of
SNPs is large and comparable with the sample size (e.g. PRS including
~87 K SNPs (Escott-Price et al., 2015b), M ~ 74 K in the International
Genomics of Alzheimer's Project (IGAP) (Lambert et al., 2013)), the
ratio M/(Nh2) is not small. Therefore, the R2 value is (much) smaller
than the SNP-based heritability. For example, the expected E
(R2) ~ 0.04 for AD (using M and N from the example above and
h2 = 0.24), which is similar to the results reported in (Escott-Price
et al., 2015b). Thus, the APOE locus alone has both a higher R2 and
AUC than a PRS without APOE, whereas the SNP-based heritability
explained by the APOE region is much lower (0.05–0.13) than that
explained by the whole genome (0.24–0.53) (Escott-Price et al., 2017b;
Lee et al., 2013a; Ridge et al., 2016).
In addition, there are two types of genetic heritability: broad sense
and narrow sense (the latter is also known as a SNP-based heritability).
Narrow sense heritability is the proportion of variation in the trait that
can be explained by only additive effects of common SNPs, so it is almost
always less than the total heritability that could be explained by all
genetic factors (broad sense) (Wray and Visscher, 2008). The narrow
sense heritability does not account for rare variants, Copy Number
Variations (CNVs), SNPxSNP interactions, dominance, etc.
To date, the broad sense heritability was reported for AD (0.58–0.79
(Gatz et al., 2006)), PD (0.27 (Goldman et al., 2019)) and ALS (Al-
Chalabi et al., 2010; Wingo et al., 2011), whereas the SNP-based her-
itability was estimated as 0.24–0.53 (Lee et al., 2013a; Ridge et al.,
2016), 0.16–0.26 (Nalls et al., 2019) and 0.21 (Keller et al., 2014),
respectively. We emphasise that these are different types of heritability
estimates, and there is no inherent contradiction between them. Indeed,
taking AD again as an example, Gatz et al. (2006) explore the co-oc-
currence of clinically diagnosed AD in families with monozygotic and
dizygotic twins, and thus estimated the broad sense heritability. In their
study, the 0.58 heritability estimate has a very broad 95% confident
interval (CI) [0.19–0.87], and the 0.79 [95% CI: 0.67–0.88] heritability
estimate is obtained using a model where the “shared environmental
influences” parameter is dropped (see Table 2 in (Gatz et al., 2006)).
The shared component in neurodegenerative disorders may not be as
essential to account for as for neurodevelopmental disorders, however
in light of known association of e.g. AD PRS with educational attain-
ment (EA) (Hagenaars et al., 2016), it may still be relevant.
SNPs, and in turn PRS, estimate/capture the narrow sense
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heritability. PRS picks up the narrow sense heritability in AD quite well
(Escott-Price et al., 2017b). To compare (Gatz et al., 2006) and (Lee
et al., 2013a) estimates, the difference between “heritability on ob-
served scale” versus “heritability on liability scale” needs to be ac-
counted for. A binary trait (case/control) has to be treated as if it has an
underlying continuous liability. PRS has a continuous normal dis-
tribution in a population, and only individuals at the right tail of the
distribution are likely to develop AD. In case/control studies we esti-
mate “heritability on observed scale”. To project it to the whole po-
pulation, the “heritability on observed scale” must be converted to the
“heritability on liability scale”, accounting for the disease prevalence as
follows = −
−
h hLiab obs
K K
Z P P
2 2 [ (1 )]
(1 )
2
2 , where hLiab
2 is the heritability estimate on
liability scale, K is the prevalence of the disease, P is the proportion of
cases in the study and hobs2 is the heritability estimate on observed
scale. Z is the liability threshold defined by the standard normal dis-
tribution depending on the prevalence K (see eq. (23) from (Lee et al.,
2011)). For AD in case/control data, the (Lee et al., 2013a) approach
estimates the narrow sense heritability on liability scale as 0.24 (as-
suming a disease prevalence (lifetime risk) of 2% for AD (Brookmeyer
et al., 1998). The Gatz et al. approach estimates the broad sense her-
itability on liability scale (Gatz et al., 2006) and their sample was 65+
years. The AD prevalence in 65+ age group is 10% (Thies and Bleiler,
2012), so the h2 on the liability scale assuming a disease prevalence
(65+) of 10%, is ~0.39. This narrow sense heritability on liability scale
is, as expected, lower than Gatz et al.'s broad sense heritability estimate
and falls within its confidence intervals. The same applies to heritability
estimates for other reported neurological disorders. The broad sense
heritability of PD (0.27 (Goldman et al., 2019)) is within the interval of
the reported narrow sense heritability (0.16–0.36 (Nalls et al., 2019)),
and for the ALS the estimates are not so close (0.4–0.76 (Al-Chalabi
et al., 2010; Wingo et al., 2011) and 0.21 (Keller et al., 2014) for the
broad and narrow sense heritability, respectively).
4. Pleiotropy in neurodegeneration
Several studies have been conducted in an effort to investigate
mostly the genetic overlap between traits in neurological disorders, and
consequently identify novel genetic associations.
Genetic overlap and pleiotropy between neurodegenerative diseases.
The Brainstorm Consortium, a collaboration among GWAS meta-
analysis consortia for 25 disorders, performed a comprehensive herit-
ability and correlation analysis of brain disorders (Anttila et al., 2018).
Neurological disorders showed a limited extent of genetic correlation
compared to psychiatric disorders, suggesting greater diagnostic spe-
cificity and/or more distinct aetiologies. PD, AD, generalised epilepsy,
and multiple sclerosis showed little to no correlation with other brain
disorders. Interestingly, despite AD and PD being clinically distinct
entities, there is pathological evidence of Lewy body deposition (which
is central to DLB) in AD that has been reported to be more extensive in
familial AD cases and in AD cases with a variant pathology (Lippa et al.,
1997). Similarly, an AD-like pathology has been reported in some PD
cases, with a correlation being found between cortical amyloid pa-
thology, neurofibrillary tangle pathology, and dementia in PD (Compta
et al., 2011). Guerreiro et al. (2016) compared AD and PD summary
GWAS statistics using restricted maximum likelihood and obtained a
statistically significant but relatively low genetic correlation rg = 0.08
(Guerreiro et al., 2016). This study however showed a significant ge-
netic correlation between AD and DLB (rg = 0.578) and between PD
and DLB (rg = 0.362). The former correlation remained substantial
(rg = 0.332) even when the APOE locus was excluded. The PD-DLB-AD
spectrum may share some underlying mechanisms; however, the ab-
sence of genetic overlap between AD and PD reported by Guerreiro
et al. (2016) might be indicative of different biological pathways un-
derlying the association between DLB and AD and PD. Finally, the au-
thors presenting the GNOVA technique identified a significant
correlation between AD and ALS using both their method and LDSC
(rg = 0.175 and rg = 0.12, respectively) (Lu et al., 2017). A potential
common neuroinflammation pathway, underlying both diseases, was
suggested after tissue-stratified analysis, with covariance showing sig-
nificance in the immune annotation track (p-value = .014). The results
above show weak to moderate evidence for genetic correlations be-
tween neurodegenerative disorders, but do not explicitly indicate the
molecular mechanisms of the disease development.
Further attempts were made to identify specific loci and genes in-
dicating pleotropic effects, as the absence of genetic overlap between
traits at the genome-wide level does not implicate the absence of
pleiotropic genes/SNPs. Although advancing age is a common risk
factor for both AD and PD, studies that have investigated the extent to
which these two diseases co-occur in families have produced varying
results. A study by Moskvina et al. (Moskvina et al., 2013) revealed no
significant evidence for the presence of alleles that increase the risk of
both diseases. The authors of another study (Desikan et al., 2015) re-
ported genetic overlap between AD and PD at the tau-associate MAPT
locus (variant rs393152) and conducted an enrichment analysis in AD
as a function of significance in PD with cFDR with and without MAPT
locus. Removing MAPT, there was a considerable attenuation of en-
richment, so the observed pleiotropy was non-polygenic and confined
to the MAPT region. The reported variant, that tags the H1 haplotype at
MAPT locus which has been associated with various tauopathies
(Pittman et al., 2006), was also significantly associated with long-
itudinal medial temporal lobe atrophy. Finally, a study assessed the
genetic overlap between frontotemporal dementia (FTD), AD and PD
using conjunction cFDR and identified novel FTD risk associated mar-
kers using cFDR (Ferrari et al., 2017). Polygenic enrichment was ob-
served for FTD SNPs conditional on AD and PD across different sig-
nificance levels providing evidence of pleiotropy. A similar pattern was
observed for AD SNPs and PD SNPs conditional on FTD. Moreover,
eight loci were found to be FTD-PD specific, one to be FTD-AD specific
and 13 novel FTD associations were identified within the HLA, MAPT
and APOE regions. The findings support the role of immune response,
lysosomal processes, intracellular vesicular trafficking and chromatin
metabolism in neurodegenerative diseases (Ferrari et al., 2017).
4.1. Genetic overlap and pleiotropy between neurodegenerative and
neurodegenerative-associated traits
A number of studies have investigated phenotypic links between AD
and known associated phenotypes including EA, cognitive impairment
and neuropathological traits. Using 112,151 participants of the UK
Biobank, the pleiotropic effects between cognitive functioning and AD
were quantified using both LDSC and PRS analysis (Hagenaars et al.,
2016). Significant negative correlations were found with verbal-nu-
merical reasoning (rg = −0.39) and with EA (rg = −0.27), respec-
tively. The PRS analysis replicated the latter results; higher polygenic
risk for AD was associated with lower score on verbal-numerical rea-
soning (size effect β = −0.023, p = 1.27 × 10−5), more errors on a
short-term recall task (β = −0.011, p = 1.22 × 10−4), and lower EA
(β = −0.046, p = 2.33 × 10−12). Similar results were reported in a
similar study using LDSC using data from the CHARGE consortium (Hill
et al., 2016). AD was negatively correlated with both childhood and old
age general cognitive function (rg = −0.341, p = .001 and
rg = −0.324, p = 1.78 × 10−5, respectively), and with EA
(rg = −0.324, p = 1.15 × 10−5). Lu et al. (2017) jointly analysed AD
and other 49 traits and reported significant negative correlations be-
tween cognition and EA. No significant correlations were found be-
tween AD and trait neuroticism or diseases like depression and schi-
zophrenia (Lu et al., 2017). In 2018, Hagenaars et al. repeated their
analyses using the UK Biobank, focusing on the overlap of AD, ALS and
FTD with cognitive ability and physical function (Hagenaars et al.,
2018). PRS for AD significantly predicted, as before, verbal-numerical
reasoning and short-term recall. When the APOE region was excluded,
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the results remained significant. Moreover, higher ALS PRS was sig-
nificantly associated with answering fewer verbal-reasoning questions
correctly (β = −0.019). In a meta-analysis study for general cognition
function, SNPs in a number of genes were identified which have also
been implicated in Alzheimer's disease, including SLC39A1 (Olesen
et al., 2016), TTBK1 (Ikezu and Ikezu, 2014), MAPT, WNT3, CRHR1,
KANSL1, and NSF (Jun et al., 2016). Furthermore, using LDSC the es-
timated genetic correlation between AD and cognition was found to be
rg =−0.37 with p= 2.78 × 10−5 (Davies et al., 2018). The protective
relationship between EA and AD was replicated using Mendelian ran-
domization using 1271 SNPs (odds ratio = 0.63, 95% CI: 0.54–0.74;
p = 4.08 × 10−8) (Raghavan et al., 2019), and the regions that re-
plicated the causal relationship were found to contain genes involved in
the regulation of the neural development. The common underpinnings
of cognition and health measures support the theoretical hypothesis of
bodily system integrity (Deary, 2012). The latter is based on the idea
that there is a latent trait of well-functioning body with, for example,
higher levels of cognitive function being one aspect of that body that
can respond well to environmental challenges and be resistant to dis-
ease.
Chung et al. (2018) conducted genome-wide pleiotropy analyses
using GWAS summary statistics for AD-related neuropathological traits,
including neuritic plaque (NP), neurofibrillary tangle (NFT), and cere-
bral amyloid angiopathy (CAA). Genome-wide significant pleiotropic
associations were observed for a single SNP in the joint models of NPs
and NFTs; and for NFTs and CAA at SNP and gene-based levels (Chung
et al., 2018). Both identified regions, C20orf40 and HDAC9, showed
reduced expression in subjects with AD compared to controls in several
brain regions. The authors also suggested that HDAC9 along with
MEF2C, a well-established AD risk loci (Lambert et al., 2013), might
participate in a pathway leading to the formation of neurofibrillary
tangles and brain atrophy (Chung et al., 2018). Finally, in a recent
study the overlap between brain age gap and brain disorders was as-
sessed (Kaufmann et al., 2019). No genetic correlation estimated with
LDSC was significant after applying FDR correction for multiple testing;
however, when using cFDR, six significant independent loci were found
showing genetic overlap between brain age gaps and AD.
4.2. Genetic overlap and pleiotropy between neurodegenerative and non-
degenerative diseases
There have also been a number of studies showing genetic overlap
between AD and non-neurodegenerative disorders; in particular AD and
bipolar disorder (BIP), implicating the MARK2 and VAC14 genes using
cFDR analysis (Drange et al., 2019), AD and breast and lung cancer
using LDSC (rg = 0.18, p = .03 and rg = 0.30, p = .01, respectively)
(Feng et al., 2017), and AD family history and depression, although this
showed a non-significant correlation (Gibson et al., 2017). Both MARK2
and VAC14, jointly involved in the genetic aetiology of AD and BIP,
have been described to play a role in neuronal migration, tau phos-
phorylation (Gu et al., 2013; Matenia and Mandelkow, 2009; Reiner
et al., 2009) and endosomal homeostasis (Di Paolo and De Camilli,
2006), whereas the regulation of gene expression in relation to en-
hancer activity might play a crucial role in the shared heritability of AD
and cancer (Feng et al., 2017). In a study conducted to explore the share
genetics between AD and cardiovascular disease (CAD), and ad-
ditionally between their shared risk factors and each disease (Karlsson
et al., 2017), the authors using polygenic scores found no association
between CAD PRS and dementia after controlling for age, sex, educa-
tion, and diabetes and no common cluster of significant genes for AD
and CAD. AD and CAD each had a significant number of genes in
common with low density lipoprotein cholesterol and total cholesterol,
but not with the same genes, whereas only AD overlapped with high-
density lipoprotein cholesterol and triglycerides. Additionally, AD and
Body Mass Index (BMI) were found to have a significant number of
shared genes, whereas no genetic overlap was found between AD and
Type 2 Diabetes (T2D). Similarly, Proitsi et al. found no association
between the PRSs based on T2D and the increased risk of AD (Proitsi
et al., 2014). It has been suggested that beta amyloid plaques and
metabolic changes precede dementia (Jack et al., 2009), thus T2D
might be a metabolic consequence of AD.
Broce et al. (2019) studied the shared genetic variance between AD
and CVD associated risk factors including BMI, T2D, CAD, waist hip
ratio (WHR), lipid levels like high-density lipoprotein (HDL) and low-
density lipoprotein (LDL), total cholesterol (TC), and triglycerides (TG)
(Broce et al., 2019). Using the cFDR approach, they reported a pleio-
tropic genetic enrichment of significant SNPs for the plasma lipid levels
and 90 SNPs that are jointly associated with increased risk of AD and
CVD outcomes. High plasma lipid levels are thought to possibly lead to
pathological cholesterol metabolism in the brain (Xue-Shan et al.,
2016). Finally, Lin et al. (2019) used AD PRS to examine the polygenic
overlap between AD and vascular pathologies including lobar cerebral
microbleeds (CMB), white matter lesions (WML), retinal venular dia-
meter, carotid intima-media thickness and coronary artery classifica-
tion (CAC). Their findings were mostly due to APOE, which showed an
association with CMB, WML and CAC, and two cognition outcomes (Lin
et al., 2019).
Investigating the relationship between PD and autoimmunity using
cFDR and conjunction cFDR (Witoelar et al., 2017), 17 novel genetic
variants were found to be common with type 1 diabetes, Crohn's dis-
ease, ulcerative colitis, rheumatoid arthritis, celiac disease, psoriasis,
and multiple sclerosis, suggesting that the immune system affects the
PD aetiology. Since then, a positive and significant correlation has been
found between PD and PD-inferred gene expression and melanoma
(rg = 0.17 and rg = 0.14, respectively) (Dube et al., 2019).
5. Discussion
The existence of pleiotropy suggests that common pathological
mechanisms may underlie neurodegenerative disorders. While neuro-
degenerative diseases have distinct pathologies, there are also shared
pathological features like protein aggregation in the brain. It has also
become apparent that common pathways exist in the pathogenesis of
neurodegeneration: aberrant ion channel function, mitochondrial dys-
function, defects in intracellular trafficking and axonal transport, ab-
normal protein aggregation and clearance (Hashimoto et al., 2018). In
addition, the association between inflammation and neurodegenerative
diseases has long been observed in AD, ALS and PD (Witoelar et al.,
2017). Given the various molecular mechanisms that can drive the
association of the shared genetic risk variants, the biological inter-
pretation of pleiotropy is challenging. With the increased availability of
GWAS summary statistics over the last decade, the phenomenon of
pleiotropy and its exploitation has received increasing attention as
pleiotropy may inform reasons for comorbidity between traits, pointing
to underlying shared biological pathways, and thus may aid in orienting
the causality between traits.
Medical treatments and interventions for neurodegenerative dis-
eases typically use a ‘one-size-fits-all’ approach, in which broad treat-
ment programmes are recommended to all patients. Given the complex
and heterogeneous nature of diseases such as AD, there is great po-
tential to improve these treatments though the use of precision medi-
cine. Precision medicine is an approach whereby the individual char-
acteristics of a patient, their specific genotype or phenotype, and
progression stage of the disease are taken into account to suggest the
most appropriate medical treatment. This approach is widely used, for
example, in oncology (Garraway et al., 2013). Although broadly
thought of in the public domain as one entity, cancers exhibit a range of
aetiologies, progressions, and presentations depending on their type.
Thus, different medical treatments are provided dependent on the type
and stage of cancer, and the characteristics of the patient being treated.
Application of similar methods in Alzheimer's disease would better re-
present the varied nature of this and similar dementias and
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neurodegenerative diseases.
At present the largest obstacle for precision medicine approaches in
neurodegenerative disorders is the relative infancy of research into the
causes of these disorders, in particular at a molecular level. Polygenic
risk scores as a tool to model pleiotropic loci for disease and its sub-
phenotypes have a great potential to contribute to precision medicine
for neurodegenerative disorders. As GWASs examine the entire genome,
in combination with pleiotropy they have the ability to highlight pre-
viously unknown genes, and to examine their association with a
number of phenotypes directly related to the disease and/or phenotypes
which are consequences of disease development and progression.
In conclusion, the molecular mechanisms underlying pleiotropy is
likely to be diverse and understanding of these mechanisms is vital for
understanding pathogenesis of neurodegenerative disorders. Pleiotropy
in combination with the risk prediction utility of PRS, this can form the
foundation stones upon which precision medicine for neurodegenera-
tive disorders is built. Hence, research utilising these approaches is
crucial for initiatives aiming to bring precision medicine to the field of
neurodegenerative disease. The associations between pathway specific
PRS and phenotypic changes, accounting for insights from pleiotropy,
may allow us to define the biology of disease in individuals, heralding
precision medicine in neurodegeneration.
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